Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook

Friday, AbbVie Inc (NYSE:ABBV) reported first-quarter adjusted EPS of $2.31, down 6.1% Y/Y, beating the consensus of $2.23.Net revenues reached $12.31 billion, up 0.7%, beating the consensus of $11.92

BenzingaApr 26 21:54

Stockholder Alert: Ademi LLP Continues Investigation of the Fairness of Landos Biopharma, Inc.'s Transaction With AbbVie

MILWAUKEE, April 16, 2024 /PRNewswire/ -- Ademi LLP investigation of Landos (NASDAQ: LABP) continues now that Landos has filed a preliminary proxy statement seeking stockholder approval for its trans

PR NewswireApr 17 03:32

Landos Biopharma Cut to Neutral From Buy by HC Wainwright & Co.

Landos Biopharma Cut to Neutral From Buy by HC Wainwright & Co.

Dow JonesApr 1 19:22

HC Wainwright & Co. Downgrades Landos Biopharma to Neutral, Lowers Price Target to $20.42

HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Landos Biopharma (NASDAQ:LABP) from Buy to Neutral and lowers the price target from $50 to $20.42.

BenzingaApr 1 19:12

Landos Biopharma Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/01/2024 -4.67% HC Wainwright & Co. $50 → $20.42 Downgrades Buy → Neutral 01/06/2023 -99.53% Jefferies $

BenzingaApr 1 19:04

Maintaining Hold Rating on Landos Biopharma Amid Acquisition by AbbVie and Limited Upside Potential

TipRanksApr 1 18:17